END Thyroid miscellany Dr SS Nussey © S Nussey and ios
Thyroid hormone transport
Thyroid hormone metabolism Box 3.29
Thyroid hormone assay
TSH Assay
Implications
Thyroid hormone assay - potential problems Protein-tracer interactions e.g. immunoglobulins (IgG) Dilution effects and protein dependence Substances competing with T4 for binding to binding proteins or IgGs e.g. fatty acids As a result the TSH assay is more robust in many clinical situations (though more expensive) Population screening?
Non-thyroid illness aka ‘Sick euthyroid syndrome’
Drugs and the thyroid gland
Clinical implications of non- thyroid illness
Amiodarone and the thyroid Effects: –Source of iodine –Thyroid cytotoxic –Inhibitor of type 1 and 2 deiodinases –Antagonise thyroid hormone action Clinically, may cause hypo- or hyper- thyroidism
(‘Non-autoimmune’) Thyroiditis Includes - sporadic (silent); subacute (DeQuervain’s); post-partum; fibrous (Riedel’s) Genetic, clinical, histopathological differences Clinical course of transient thyrotoxicosis, hypothyroidism and then recovery Investigations show - elevated serum thyroid hormones, suppressed TSH, reduced 99m Tc uptake and elevated Tg + elevated ESR Treatment
Subclinical hyperthyroidism
TSH assays Limits of detection –First generation -1.0mU/l –Second generation -0.1mU/l –Third generation mU/l –Fourth generation mU/l Normal range mU/l
Definition ‘Sustained thyrotrophin concentration <0.01mU/l with normal concentrations of free thyroxine and tri-iodothyronine in the absence of hypothalamo- pituitary dysfunction or non-thyroidal illness’
Prevalence Large scale community studies % Increases with: age, being female and nodular thyroid disease Most common cause - thyroid hormone replacement (~20-40%) In those not due to thyroid hormone treatment, progression to clinical hyperthyroidism is infrequent
Effects Lancet 2001, 358:861
Circulatory disease
Atrial fibrillation Original Framingham cohort of Age >60 Excluded those taking thyroxine or treated thyroid disease TSH assay - Low (<0.1mU/l), ‘Slightly low’ ( mU/l), Normal (0.4-5mU/l), High (>5mU/l)
Atrial fibrillation
Implications Assuming that treatment prevents AF, 4.2 cases would need to be treated to prevent 1 case of AF. Note: –there is only limited evidence that AF reverts spontaneously or after DCC once the TSH has been normalised –ranges of embolism in thyrotoxic AF - ‘negligible’ to 40% (mean 10-15%) - is the risk the same? –no (clinical trial) evidence for efficacy of warfarin
Bone density Clinical hyperthyroidism is known factor in osteoporosis Effects of subclinical hyperthyroidism are uncertain Needs longitudinal study J Clin Endocrinol Metab 1996, 81:4278
Subclinical hypothyroidism
Definition ‘Sustained thyrotrophin concentration >4 mU/l with normal concentrations of free thyroxine and tri-iodothyronine in the absence of symptoms and signs of hypothyroidism’
Prevalence Large scale community studies % Increases with: age, being female and in areas of higher iodine intake Causes as for clinical hypothyroidism Progression to clinical hyperthyroidism is high (~5% per annum)
Causes of hypothyroidism
Implications NB - Cross-sectional study - Previous smaller studies had failed to show an effect
Treatment BMJ 2001,323: 891 Treatment in subclinical hypothyroidism: –reduces goitre by ~80% –improves memory and wellbeing –reduces total and HDL cholesterol slightly
‘Hot topic’ Lancet 2001, 2034
Background Thyroid diseases are more common in females and may be exacerbated by pregnancy Are these auto-immune or allo-immune i.e. graft-versus-host? In women with scleroderma there is an increase in male cells in the skin (presumably from fetal transfer) Is there a similar increase in male cells in the thyroid glands of women with thyroid disease?
Methods Archival thyroid gland pathological paraffin sections 29 patients; controls from 8 necropsies FISH - X - red signal; Y - green signal
Results Cells with both X and Y seen in 16 of 29 thyroid patients but none of controls 12 of 20 (63%) patients with at least one male child had male cells in the thyroid
Origin of male cells in female thyroid Male stem cells from fetal-maternal transfusion during pregnancy, labour, delivery. Male stem cells from a twin gestation, organ transplant or blood transfusion Artefact